The latest price target for Vertex Pharmaceuticals (NASDAQ:VRTX) was reported by Maxim Group on March 18, 2026. The analyst firm set a price target for $575.00 expecting VRTX to rise to within 12 months (a possible 32.40% upside). 62 analyst firms have reported ratings in the last year.

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by Maxim Group, and Vertex Pharmaceuticals upgraded their buy rating.

The last upgrade for Vertex Pharmaceuticals Inc happened on March 18, 2026 when Maxim Group raised their price target to $575. Maxim Group previously had a hold for Vertex Pharmaceuticals Inc.

The last downgrade for Vertex Pharmaceuticals Inc happened on May 6, 2025 when Leerink Partners changed their price target from $550 to $503 for Vertex Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vertex Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vertex Pharmaceuticals was filed on March 18, 2026 so you should expect the next rating to be made available sometime around March 18, 2027.

While ratings are subjective and will change, the latest Vertex Pharmaceuticals (VRTX) rating was a upgraded with a price target of $0.00 to $575.00. The current price Vertex Pharmaceuticals (VRTX) is trading at is $434.30, which is within the analyst’s predicted range.